Protein Degradation with PROTAC Protein Degraders | Arvinas
Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
PROTAC Protein Degrader Pipeline - Arvinas
In April 2024, Arvinas entered into a global license agreement with Novartis for the development and commercialization of PROTAC® androgen receptor (AR) protein degrader ARV-766 for the treatment of prostate cancer. The deal also includes the sale of the AR-V7 program to Novartis . …
About - Arvinas
At Arvinas, we work every day to unlock the full potential of PROTAC® protein degraders, developing a robust pipeline and partnering with the world’s leading drug development companies to bring new possibilities where they are needed most.
Press Releases - Arvinas
2024年6月17日 · Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
Careers - Arvinas
If you’re inspired, please take a look at the current list of opportunities to join our team. We’re really excited about the work we’re doing inside and outside of Arvinas. If you think one of these positions is a fit, we’d love to hear from you.
Open Positions | Arvinas
We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.
The Arvinas PROTAC® Discovery Engine: PROTAC biophysical characterization fuels the discovery of target and E3 ligase ligands for optimized PROTAC degrader molecules.
Events and Presentations - Arvinas
2024年9月5日 · Guggenheim Securities Healthcare Innovation Conference. November 13, 2024 2:00 PM EST. Listen to webcast. Add to Outlook. Add to Google Calendar.
Arvinas Enters into a Transaction with Novartis, including a Global ...
2024年4月11日 · Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer.
Leadership| Arvinas
Our leadership, board of directors, and scientific advisory board are comprised of accomplished drug hunters and experts in the biotechnology and pharmaceutical industries.
- 某些结果已被删除